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Abstract  
Objective: Characterization of the clinical features of patients with persistent 
symptoms after mild to moderate COVID-19 infection and exploration of factors 
associated with the development of Chronic COVID-19 Syndrome (CCS).  
Methods: Setting: Charité Fatigue Center with clinical immunologists and 
rheumatologist, neurologists and cardiologists at Charité University hospital. 
Participants: 42 patients who presented with persistent moderate to severe fatigue six 
months following a mostly mild SARS-CoV-2 infection at the Charité Fatigue Center 
from July to November 2020.  
Main outcome measures: The primary outcomes were clinical and paraclinical data 
and meeting diagnostic criteria for Chronic Fatigue Syndrome (ME/CFS). Relevant 
neurological and cardiopulmonary morbidity was excluded. 
Results: The median age was 36.5, range 22–62, 29 patients were female and 13 
male. At six months post acute COVID-19 all patients had fatigue (Chalder Fatigue 
Score median 25 of 33, range 14–32), the most frequent other symptoms were post 
exertional malaise (n=41), cognitive symptoms (n=40), headache (n=38), and muscle 
pain (n=35). Most patients were moderately to severely impaired in daily live with a 
median Bell disability score of 50 (range 15–90) of 100 (healthy) and Short Form 36 
(SF-36) physical function score of 63 (range 15-80) of 100. 19 of 42 patients fulfilled 
the 2003 Canadian Consensus Criteria for myalgic encephalomyelitis/chronic fatigue 
syndrome (ME/CFS). These patients reported more fatigue in the Chalder Fatigue 
Score (p=0.006), more stress intolerance (p=0.042) and more frequent and longer post 
exertional malaise (PEM) (p=0.003), and hypersensitivity to noise (p=0.029), light 
(p=0.0143) and temperature (p=0.024) compared to patients not meeting ME/CFS 
criteria. Handgrip force was diminished in most patients compared to healthy control 
values, and lower in CCS/CFS compared to non-CFS CCS (Fmax1 p=0.085, Fmax2, 
p=0.050, Fmean1 p=0.043, Fmean2 p=0.034, mean of 10 repeat handgrips, 29 female 
patients). Mannose-binding lectin (MBL) deficiency was observed frequently (22% of 
all patients) and elevated IL-8 levels were found in 43% of patients.  
Conclusions: Chronic COVID-19 Syndrome at months 6 is a multisymptomatic 
frequently debilitating disease fulfilling diagnostic criteria of ME/CFS in about half of 
the patients in our study. Research in mechanisms and clinical trials are urgently 
needed. 
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INTRODUCTION 
Infection with severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) 
poses a major threat for developing chronic morbidity. While older patients or those 
with risk factors have a high risk of severe or critical COVID-19 (Corona Virus Disease) 
mortality and morbidity, in about 80% of cases COVID-19 is mild according to WHO 
criteria. Soon there were reports, however, of patients with persistent symptoms 
following mild COVID-19 referred to as long COVID.1 2 Frequent symptoms that were 
reported are fatigue, impaired physical and cognitive function, headache, 
breathlessness, palpitations and many other symptoms, impairing activities of daily 
living in many patients.3-7 A recent publication of a patient survey of long COVID in 
younger patients described diverse symptoms with fatigue, post-exertional malaise 
(PEM), and cognitive dysfunction as most frequent requiring a reduced work schedule 
in almost half and inability to work in 22% of patients.3 PEM describes an intolerance 
to mental and physical exertion, which triggers an aggravation of symptoms typically 
lasting for more than 14 hours up to several days8. 
Long-term health consequences following mild COVID-19 are largely unknown yet but 
have been feared based on observations from SARS-CoV-1. Here many patients were 
reported who developed a severe post-infectious syndrome with persistent fatigue, 
muscle pain, shortness of breath and mental symptoms independent of illness 
severity.9 Various pathogens including Epstein Barr Virus (EBV), enteroviruses, and 
dengue viruses are known to trigger chronic fatigue syndrome/myalgic 
encephalomyelitis (ME/CFS) in a subset of patients.10 It is unclear yet, if 
pathomechanisms of post-infectious fatigue syndromes may be different depending on 
the pathogen.  
ME/CFS is a debilitating chronic disease with a worldwide prevalence of 0.3 to 0.8%.11 
Profound mental and physical fatigue, sleep disturbance, and chronic pain are key 
symptoms of ME/CFS. The best discriminating symptoms distinguishing ME/CFS from 
chronic fatigue in multiple sclerosis were flu-like symptoms and the intolerance to 
mental and physical exertion triggering PEM for more than 14 hours.12 ME/CFS is 
classified by the World Health Organization (WHO) as neurological disease with G93.3 
in the International Classification of Diseases (ICD). Although the pathomechanism is 
not well characterized yet, there is ample evidence of immune, autonomous nervous 
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system and metabolic dysregulation.13 There is emerging evidence that post-infectious 
ME/CFS has an autoimmune mechanism and dysfunctional autoantibodies to natural 
regulatory antibodies against adrenergic receptors were described.13-15  
We report here on the first results of our ongoing study initiated at Charité in July 2020 
to characterize patients with persistent fatigue and other symptoms following mild to 
moderate COVID-19 and to assess if they meet diagnostic criteria for ME/CFS. Due to 
the complexity of symptoms patients were comprehensively evaluated by a team from 
various disciplines including clinical immunology, rheumatology, neurology, cardiology, 
and pneumology with long experience in diagnosing ME/CFS (https://cfc.charite.de). 
Our findings confirm initial concerns that COVID-19 leads to persistent fatigue 
syndromes in a subset of younger individuals following mild to moderate infection. We 
describe here the clinical characteristics of the Chronic COVID-19 Syndrome (CCS) at 




MATERIAL AND METHODS 
Study protocol  
The primary objective of this monocentric prospective observational study is to 
characterize patients contacting the Charité Fatigue Center with persistent fatigue after 
COVID-19 prospectively and determine if they fulfill diagnostic criteria for ME/CFS. 
Patients were selected based on a screening questionnaire, specifying COVID-19 
diagnosis and symptoms including mild to moderate COVID-19 according to WHO 
criteria and persistent symptoms. Inclusion criteria were symptoms of moderate to 
severe fatigue and exertion intolerance, neurocognitive impairment, and pain six 
months post infection in the absence of relevant respiratory, neurological or psychiatric 
comorbidity. A subset of patients was already seen at months three and four, and 
reevaluated at month six. COVID-19 had been diagnosed by PCR (polymerase chain 
reaction) or serology (SARS-CoV 2 IgG/IgA) or if PCR was not performed and serology 
was negative clinically due to typical initial symptoms including loss of smell and taste 
(n=3). All patients signed informed consent before study assessment. This study is part 
of the Pa-COVID-19 study of Charité and approved by the Ethics Committee of Charité 
Universitätsmedizin Berlin in accordance with the 1964 Declaration of Helsinki and its 
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later amendments (EA2/066/20). Between July, 16 and November, 27 a total of 57 
patients presented at our outpatient clinics. Patients were excluded from this study in 
the presence of relevant comorbidities or preexisting fatigue, absence of confirmed 
COVID-19 or evidence of organ dysfunction. Further patients were not included in this 
report in case of pending cardiopulmonary or neurological assessment. Thus, we 
report here on the results of the cross-sectional analysis at month six in a total of 42 
patients. 
Diagnostic criteria and symptom assessment 
Severity of mental and physical fatigue was assessed using Chalder Fatigue Score. 
Disability and daily physical function was assessed by Bell disability scale and Short 
Form Health Survey (SF-36 Version 1). The Bell disability scale is scored from 0 (very 
severe, bedridden constantly)–100 (healthy).16 Frequency and the severity of PEM 
symptoms were assessed according to Cotler et al.8. Symptoms of autonomic 
dysfunction were assessed by the Composite Autonomic Symptom Score (COMPASS 
31).17 Depression and sleepiness were assessed by Patient Health Questionnaire 9 
(PHQ9) and Epworth Sleepiness Scale (ESS). According to PHQ9 patients were 
classified as minimal depressive symptoms (1-4), mild depressive symptoms (5-9), 
moderate depressive symptoms (10-14), moderately severe depressive symptoms 
(15-19), or severe depressive symptoms (20-27). According to ESS patients were 
classified as no evidence of sleep apnea 0–9, possible mild to moderate sleep apnea 
11-15, >16 possible severe sleep apnea. One patient with a PHQ9 score of >20 who 
is in ongoing psychosomatic evaluation was excluded from this report. 
A diagnosis of ME/CFS was based on Canadian Consensus criteria (CCC) and 
exclusion of other diseases, which may explain chronic fatigue and potential 
confounding comorbidities.18 In contrast to the original classification and in accordance 
with the studies of L. Jason and colleagues a minimum of 14 hours of PEM instead of 
24 hours was required for diagnosis of ME/CFS.8 Key symptoms of CCC were 
quantified using a 1–10 scale. All data was recorded using a REDCap database. 
Functional studies, imaging and laboratory values 
The handgrip strength was assessed using an electric dynamometer assessing 
maximal and mean force of ten times repeated maximal pulls (Fmax1 and Fmean1) 
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and a second assessment 60 minutes later (Fmax2 and Fmean2, ref Jäkel B et al. in 
revision, 2021). Blood pressure and heart rate was assessed sitting, and after two, five 
and ten minutes standing. Postural tachycardia syndrome (POTS) is defined as 
increase of >30 bpm or over 120 bpm over ten minutes standing.19 Most patients had 
already neurological, pulmonary and cardiac assessment before referral to our 
outpatient clinic without evidence for relevant impairment or comorbidity. In patients 
who reported moderate to severe difficulties with breathing, chest computer 
tomography (CT) and pulmonary function tests were performed. Patients who reported 
severe cognitive impairment or severe headache got a further comprehensive 
neurological assessment from our neurology team. Patients with sitting or postural 
tachycardia or elevated NT-proBNP got a cardiologic examination including ECG, 24h 
ECG and echocardiography from our cardiology team. Laboratory parameters 
including CBC, lymphoycte subsets, IL-8 in erythrocytes, mannose binding lectin 
(MBL), CrP, immunoglobulins, ANA, ENA, C3/4, anti-TPO, TSH, fT3/4, ferritin, 
creatinine, liver enzymes, ACE, NT-pro BNP were determined at the Charité 
diagnostics laboratory (Labor Berlin GmbH, Berlin, Germany). 
Patient and Public Involvement 
The German facebook group of patients with long COVID contacted us first in July 
2020 sharing their observations (https://c19langzeitbeschwerden.de/). The study 
design was developed based on frequency, type and severity of symptoms reported 
and discussed with the patient group. The possibility for local patients to participate in 
our study was communicated on their website. 
Statistical analysis 
We performed the statistical analysis with Excel GraphPad Prism 6.0. We used non 
parametric Mann-Whitney test to analyze differences between groups. For comparison 
of pulse and blood pressure at different time points we used Wilcoxon test. To exclude 
sex-related differences in hand grip strength and blood pressure, here, we evaluated 
only female subjects.  For correlation analysis we calculated non parametric Spearman 
correlation coefficients. A p-value of <0.05 was considered as statistically significant. 
Due to multiple testing p-values are considered descriptive without adjustments for 
multiple comparisons. 
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RESULTS 
Patient characteristics and disability 
We report here on 42 patients who presented to the Charité fatigue center with post 
COVID-19 fatigue at month six. Table 1 summarizes demographic characteristics of 
the study population. Most patients had mild COVID-19 (n = 32) and ten had moderate 
COVID-19 due to pneumonia.  
 
Table 1: Demographic and baseline clinical characteristics 
  CCS/CFS (n=19) CCS (n=23) 
  median range median range 
age 41 (24-62) 36 (22-57) 
sex (female/male) 14 / 5 15 / 8 
BMI 24,31 (18.1-31.8) 22.49 (18.0-36.2) 
Bell 40 (20-80) 50 (30-90) 
Chalder 26 (20-31) 23 (14-32) 
PHQ9 12 (3-19) 11 (2-18) 
ESS 9 (1-21) 9 (1-17) 
 
CCS/CFS = chronic COVID-19 syndrome/chronic fatigue syndrome; CCS = chronic COVID-19 
syndrome without fulfilling CFS criteria; BMI = body mass index (kg/m2), PHQ9 = Patient Health 
Questionnaire 9; ESS = Epworth Sleepiness Scale. 
 
None of the patients required oxygen or mechanical ventilation and all but 3 patients 
were ambulatory. Supplementary Table S1 shows the ten most frequent initial 
symptoms of COVID-19 reported by patients.  
19 patients fulfilled the Canadian Consensus Criteria (CCC) for ME/CFS. These 
patients were referred to as Chronic COVID-19 Syndrome/CFS (CCS/CFS), the other 
patients as CCS. Most CCS patients (18 of 23) did not fulfill ME/CFS criteria due to a 
duration of PEM less than 14 hours. Further eight of 23 patients did not fulfill the 
criterium neurological/cognitive symptoms. Based on PHQ9 we have no evidence of 
severe mental health issues in our study cohort. (Table 1). Two patients had an ESS 
score of >16, which may indicate sleep apnea. In one patient ESS score at month three 
was only three when she presented already with similar symptom severity, the other 
patient had an ESS score of 17. These patients were referred to further investigation 
at the sleep medicine ambulance. 
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The majority of patients were severely impaired in daily live with a median Bell disability 
score of 40 (range 20–80) of 100 (refers to healthy) and a SF-36 physical function of 
65 (range 15-90) of 100 (refers to healthy) in CCS/CFS and a Bell score of 50 (range 
30–90) and SF-36 physical function score of 60 (range 25–90) in CCS. CCS/CFS 
patients reported lower SF-36 scores for vitality, role limitations and social functioning 
(p = 0.060, 0.005, 0.082, respectively, Fig. 1). According to the Bell scale patients with 
a score of 30–50 are able to perform light work 2–5 hours a day (n=28), thus requiring 
a reduced work schedule or inability to work. Patients with a Bell score of 20 (n=3) are 
confined to bed most of the day. 
Symptom severity 
The leading symptom of fatigue was assessed by Chalder Fatigue Questionnaire 
(CFQ). Patients classified as CCS/CFS reported a significantly higher Chalder Fatigue 
Score with a median of 26 (range 20-31) compared to the other patients with a median 
23 (range 14–32, p=0.006, Fig. 1). The severity of PEM as the cardinal symptom of 
ME/CFS was the strongest discriminatory symptom. CCS/CFS patients had 
significantly more frequent episodes of PEM (p=0.016). While according to diagnostic 
criteria all CCS/CFS patients had PEM of 14 hours or more, CCS patients reported 
PEM of less than 14 hours in 18 of 23 patients, most patients reported PEM lasting 
between 2–10 hours (n=15), only one patient had no PEM as shown in Fig. 2.  
Symptom severity was assessed on a scale of 1–10 (none to severest). Table 2 shows 
the frequency and severity of all symptoms at month six in patients classified as 
CCS/CFS and CCS.  
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Table 2: Frequency and severity of symptoms at month 6 









median range p-value 
Fatigue 100 8 (5-10) 100 7 (2-10) 0.6874 
PEM 100 8 (5-10) 91 6 (1-9) 0.0074 
Need for rest 100 8 (5-10) 96 7 (1-10) 0.1446 
Impaired performance in everyday life 100 8 (4-10) 96 8 (1-10) 0.3454 
Stress intolerance 100 8 (3-10) 96 5 (1-10) 0.0420 
Muscle pain 84 5 (1-10) 83 4 (1-9) 0.6906 
Headache 95 5 (1-9) 87 5 (1-10) 0.4526 
Joint pain 89 3 (1-10) 78 3 (1-9) 0.4640 
Memory/word finding problems 100 5 (2-7) 70 5 (1-8) 0.6422 
Concentration impairment 100 6 (3-9) 91 5 (1-9) 0.2879 
Mental fatigue 100 6 (4-10) 100 7 (2-10) 0.6258 
Visual disturbances 63 3 (1-6) 48 1 (1-6) 0.4373 
Palpitations 89 5 (1-10) 70 4 (1-9) 0.4448 
Dizziness when standing up 84 5 (1-10) 83 4 (1-8) 0.5256 
Dizziness when walking 68 3 (1-7) 61 2 (1-9) 0.3169 
Sleep disturbances 89 7 (1-10) 83 6 (1-10) 0.9999 
Temperature sensitivity 79 5 (1-8) 48 1 (1-8) 0.0241 
Sensitivity to light 84 5 (1-10) 52 2 (1-7) 0.0143 
Sensitivity to noise 89 5 (1-10) 70 3 (1-9) 0.0290 
Breathing disorders 79 5 (1-10) 70 5 (1-10) 0.6710 
Irritable bowel 79 5 (1-9) 48 1 (1-10) 0.1821 
Fever 21 1 (1-10) 17 1 (1-3) 0.8714 
Painful lymph nodes 32 1 (1-9) 30 1 (1-7) 0.9186 
Sore throat 63 3 (1-7) 57 2 (1-7) 0.4096 
Flu-like feeling 79 5 (1-8) 70 3 (1-10) 0.0944 
 
CCS/CFS = chronic COVID syndrome/chronic fatigue syndrome; CCS = chronic COVID syndrome without fulfilling 
CFS criteria; PEM = post- exertional malaise. 
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Patients with CCS/CFS reported significantly more stress intolerance (p=0.042) and 
hypersensitivity to temperature (p=0.024), noise (p=0.029) and light (p=0.014) (Fig. 3 
and Table 2). All other symptoms were not significantly different in frequency and 
severity between CCS/CFS and CCS. 
Autonomic dysfunction 
The majority of patients suffer from autonomic dysfunction assessed by COMPASS-
31 score with moderate (20–40) symptoms in 21 and severe (40–60) in 11 patients. 
Severity of symptoms was not significantly different between CCS/CFS and CCS. The 
COMPASS total score and subdomains of orthostatic, gastrointestinal, vasomotor, 
pupillomotor, secretory and bladder symptoms are listed in Table 3.  
 
Table 3: COMPASS total score and subdomains 
COMPASS 31   CCS/CFS CCS 
  max. value % median range % median range 
total  100 100 39.37 (7.1-62.2) 100 26.79 (2.5-54.0) 
orthostasis 40 84 24.00 (0-40) 76 16.00 (0-40) 
vasomotor 5 26 0.00 (0-4.2) 10 0.00 (0-4.2) 
secretomotor 15 63 4.29 (0-12.9) 57 2.14 (0-10.7) 
gastrointestinal 25 89 6.25 (0-15.2) 95 6.25 (0-16.1) 
bladder 10 47 0.00 (0-3.3) 33 0.00 (0-2.2) 
pupillomotor 5 95 1.67 (0-3.3) 86 1.33 (0-3.0) 
 
CCS/CFS = chronic COVID syndrome/chronic fatigue syndrome; CCS = chronic COVID syndrome 
without fulfilling CFS criteria; COMPASS 31 = Composite Autonomic Symptom Score 
 
Hand grip strength (HGS) 
Muscle fatigue and fatigability were assessed by ten maximum HGS, which were 
repeated after 60 minutes (Fmax and Fmean1/2). Compared to reference values for 
age-matched healthy females most patients were below the cut-off values for Fmax1/2 
and Fmean1/2 discriminating HC from ME/CFS (own manuscript in revision). Patients 
with CCS/CFS had significantly lower Fmax2 and Fmean1/2 compared to CCS (Fig. 
4). Values for male patients are not shown due to low numbers. 
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Sitting and standing heart rate and blood pressure 
Heart rate and systolic and diastolic blood pressure sitting and after five minutes 
standing in female patients is shown in Fig.5. Patients with CCS/CFS had a 
significantly lower increase in systolic and diastolic blood pressure at standing 
compared to CCS. Seven patients with CFS and six with CCS had a blood pressure 
>140/90 sitting. Four patients with CCS/CFS and no patient with CCS fulfilled 
diagnostic criteria for postural tachycardia syndrome (POTS). 
Laboratory parameters 
Supplementary table S2 lists the laboratory values, which were out of normal range in 
a subset of patients. Mild lymphopenia with diminished CD4 (range from 0.31-0.49/nl. 
n=5) and or CD8 cells (n=11) was found rather frequently. Further MBL deficiency was 
more frequent with 22% in all patients compared to 5% in the general population.20 
While CrP was slightly elevated with 7.1 and 7.6 mg/l in two patients only, IL-8 in 
erythrocytes indicating elevated levels during the last three to four months was above 
the normal value in 43% of the patients. IgE was elevated in 21% of patients. Elevated 
ANA of 1:160 - 1:1280 was found in three patients in the CCS/CFS and in six patients 
in the CCS cohort. The patients were seen by a rheumatologist with no evidence for a 
rheumatic disease and ENA antibodies were not detectable in eight of eight patients. 
Deficiencies of Vitamin D and folic acid were found in 17% and 14% of patients. NT-
pro BNP was only slightly elevated in three patients (103-111ng/l). There were no 




In this study we provide evidence that COVID-19 can trigger a severe chronic 
syndrome with the hallmark of fatigue and exertion intolerance. Half of the patients 
reported here fulfill the CCC for ME/CFS.18 The others did not fulfill the CCC mostly 
due to shorter duration of PEM lasting for two to ten hours only.8 Due to the overlap 
with ME/CFS we suggest Chronic COVID-19 Syndrome as an appropriate terminology 
in accordance with another report.21 In our study, patients fulfilling the diagnostic 
criteria for ME/CFS had more severe fatigue and functional disability and reported 
more severe stress intolerance and hypersensitivity. Moreover, hand grip strength was 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted February 8, 2021. ; https://doi.org/10.1101/2021.02.06.21249256doi: medRxiv preprint 
 12 
lower in this subgroup referred as CCS/CFS, but also considerably impaired in many 
of the non-CFS patients referred as CCS. Several diagnostic criteria have been 
proposed for use in ME/CFS, of which CCC are recommended for diagnosis 
confirmation in secondary care and in research.22 Here the severity and duration of 
PEM is a key diagnostic criterion. In contrast to the original minimum length of 24 hours 
of PEM required by the CCC we set the duration criterion at 14 hours, which was shown 
to yield the highest diagnostic sensitivity and specificity to discriminate patients with 
ME/CFS from patients with fatigue due to other chronic illness.8 12 There are simpler 
criteria including the IOM and the CDC-1994/Fukuda criteria but they should be used 
for screening purposes only as both lack key symptoms required in CCC for 
diagnosis.23 24 Of note, use of such criteria would have classified more patients from 
our study as ME/CFS.  
ME/CFS is a debilitating disease leading to vast social, economic and individual 
impairments.22 People with ME/CFS have been struggling for decades to be 
recognized as having a serious and debilitating illness as many physicians are not 
familiar to diagnose and treat this disease. Despite the less severe expression of some 
symptoms in the CCS subgroup, most of the patients are severely impaired in daily 
life, too. Based on average Bell score about two thirds of patients require a reduced 
work schedule or are unable to work. This finding is in accordance with the recent 
report of a patient survey from long COVID at seven months.3  
Health sequelae of long COVID-19 may be multiple. The most relevant are post 
intensive care syndrome, pulmonary impairment, neurological deficits and 
posttraumatic stress disorder. In our patient cohort of younger patients with mostly mild 
COVID-19, we have, however, no evidence for potential confounding organ impairment 
or major depressive or anxiety diseases in accordance with other reports.25 26 A study 
from a pulmonary center recently described that patients with normal lung function 
three months after recovery from acute mild COVID-19 and with normal lung function 
exhibited more fatigue and impairment of physical functioning and as well as quality of 
life than patients who had moderate-to-critical COVID-19.26 Furthermore, in this study 
a minority of patients had evidence for depression or anxiety in line with our data, 
providing evidence that despite a high illness burden mental health is not relevantly 
impaired in most patients with CCS.  
There is still no specific treatment for ME/CFS and the knowledge of pathomechanisms 
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is fragmented due to little interest and research support.27 There is evidence of 
immune, autonomic and metabolic dysregulation in post-infectious ME/CFS.13 In line 
with these data, most patients in our study presented with symptoms of autonomic 
dysfunction. COVID-19 results in a strong inflammatory response and there is 
evidence for autoimmunity triggered by COVID-19.28 We have no evidence for ongoing 
overt inflammation as only two of the patients had mildly elevated CrP. Almost half of 
the patients had, however, elevated IL-8 levels in erythrocytes. IL-8 was significantly 
increased in critical compared to non-critical acute COVID-19.29 Elevated ANA 
antibodies in nine patients and the preponderance of females may indicate an 
autoimmune mechanism similar to ME/CFS triggered by other infections.13-15 MBL 
deficiency which has been implicated in susceptibility and course of viral infections was 
found more frequently in CCS/CFS in accordance with findings from a past study in 
ME/CFS.20  
Limitations of this study 
Our study has several limitations. Firstly, recruitment bias may have contributed to the 
severity of symptoms, thus this cohort is probably not representative for all COVID-19 
patients with persistent fatigue. Secondly, it is unclear, if the distinction into subgroups 
based on the criterion of the length of PEM indicates differences in mechanisms or 
merely reflect the variance of the disease spectrum. Thirdly, the low number of patients 
precluded detailed comparisons of phenotypes with adequate statistical power.  
 
 
CONCLUSION AND POLICY IMPLICATION 
Our study provides evidence that patients following mild COVID-19 develop a chronic 
syndrome fulfilling diagnostic criteria of ME/CFS in a subset. We must anticipate that 
this pandemic has the potential to dramatically increase numbers of ME/CFS patients. 
At the same time it offers the unique chance to identify ME/CFS patients in a very early 
stage of disease, so that interventions such as pacing and coping can be applied early 
with a better therapeutic prognosis. Further, it is an unprecedented opportunity to 
understand the pathomechanisms and characterize targets for specific treatment 
approaches.  
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Fig. 1 Severity of fatigue and disability 
Bell disability score, Chalder fatigue score and SF-36 physical function, vitality, role limitations and social 
function in 19 CCS/CFS and 23 CCS patients. Median, range and single values are shown.  
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Fig. 2 Frequency, severity and length of post exertional malaise (PEM) 
Frequency and severity of PEM was assessed on a five items scale with 0 – 20 points (none to severest) 
and the length in seven categories (from <1h to 2 – 3 days) according to Cotler.8 Median, range and 
single values are shown in 19 CCS/CFS and 23 CCS patients. 
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Fig. 3 Severity of symptoms 
Severity of symptoms was assessed on a 1 – 10 Likert scale (none to severest). Median, range and 
single values are shown in 19 CCS/CFS and 23 CCS patients. 
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Fig. 4 Hand grip strength (HGS) 
Fmax1 and fmean1 (of 10 repeat Fmax) and repeat assessment after 60 minutes (Fmax2 and Fmean2). 
Median. range and single values are shown in 14 female CCS/CFS and 15 female CCS patients. Cut-
off values of AUC reference values for age-matched healthy females are shown as dashed lines (<40 
years black dots and narrower dashed lines. >40 years white dots and wider dashed lines.). 
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Fig 5 Sitting and standing heart rate and blood pressure 
Heart rate and systolic and diastolic blood pressure sitting and after five minutes standing. Single values 
are shown in 14 female CCS/CFS and 15 female CCS patients.  
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Supplemental material 
Supplementary table S1: ten most frequent initial symptoms of COVID-19 reported 
by patients 
 
  CCS/CFS CCS  all patients 
  male female total 
% of 
CCS/CFS male female total 
% of 
CCS   
% of all 
patients 
n 5 14 19   8 15 23   42   
fatigue/malaise 4 9 13 68 7 15 22 96 35 83 
fever/higher 
temperature 3 9 12 63 6 10 16 70 28 67 
cough 2 8 10 53 7 8 15 65 25 60 
resp. problems 2 8 10 53 5 9 14 61 24 57 
loss of smell 0 10 10 53 5 8 13 57 23 55 
loss of taste 0 10 10 53 4 8 12 52 22 52 
headache 2 9 11 58 2 9 11 48 22 52 
arthralgia 0 8 8 42 2 7 9 39 17 40 
chest pain 2 6 8 42 3 6 9 39 17 40 
GI-symptoms 1 8 9 47 1 6 7 30 16 38 
 
CCS/CFS = chronic COVID syndrome/chronic fatigue syndrome; CCS = chronic COVID syndrome 
without fulfilling CFS criteria; GI = gastrointestinal. 
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Supplementary table S2: Laboratory parameters 
 
  CCS/CFS (n = 19) CCS (n = 23) 
Lab Value n % n % 
NK-cell high 1 5 0   
NK-cell low 0   1 4 
CD-4 Cell low 1 5 4 17 
CD-4 Cell high 2 11 1 4 
CD-8 Cell low 3 16 8 35 
CD-8 Cell high 2 11 0   
MBL deficiency 4 21 5 22 
sol. IL2 receptor high 1 5 1 4 
IL-8 after erylyse high 6 32 12 52 
IgA high 2 11 1 4 
IgM high 2 11 2 9 
IgE high 4 21 5 22 
IgG3 low 2 11 1 4 
IgG3 high 1 5 0   
IgG2/4 high 1 5 0   
IgG1 high 0   1 4 
IgG2 high 0   1 4 
IgG4 high 0   2 9 
elevated CRP 1 5 1 4 
elevated NT-pro BNP 2 11 1 4 
low C3 1 5 3 13 
Vit D low 2 11 5 22 
folic acid low 2 11 4 17 
ANA positive (1:160) 2 11 3 13 
ANA positive (1:320) 0   2 9 




 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted February 8, 2021. ; https://doi.org/10.1101/2021.02.06.21249256doi: medRxiv preprint 
